Home - Products - Others - Other Targets - Chrysin 7-O-beta-gentiobioside

Chrysin 7-O-beta-gentiobioside

CAS No. 88640-89-5

Chrysin 7-O-beta-gentiobioside( Chrysin 7-O-β-gentiobioside )

Catalog No. M28253 CAS No. 88640-89-5

Chrysin 7-O-beta-gentiobioside, a glycosylation product of Chrysin, is from Spartium junceum.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 205 Get Quote
10MG 329 Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Chrysin 7-O-beta-gentiobioside
  • Note
    Research use only, not for human use.
  • Brief Description
    Chrysin 7-O-beta-gentiobioside, a glycosylation product of Chrysin, is from Spartium junceum.
  • Description
    Chrysin 7-O-beta-gentiobioside, a glycosylation product of Chrysin, is from Spartium junceum.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    Chrysin 7-O-β-gentiobioside
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    COX
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    88640-89-5
  • Formula Weight
    578.52
  • Molecular Formula
    C27H30O14
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3cc(O)c4c(c3)oc(cc4=O)-c3ccccc3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Obach RS, et al. In vitro metabolism and covalent binding of enol-carboxamide derivatives and anti-inflammatory agents sudoxicam and meloxicam: insights into the hepatotoxicity of sudoxicam. Chem Res Toxicol. 2008 Sep;21(9):1890-9.
molnova catalog
related products
  • Bimagrumab

    Bimagrumab (BYM338) is a human monoclonal antibody that binds to the activin type II receptor. Bimagrumab can be used to study diabetes and obesity.

  • BAY 2402234

    BAY 2402234 (BAY2402234) is a novel potent, selective, orally bioavailable DHODH inhibitor with IC50 of 1.2 nM.

  • Mogroside III-A2

    Mogroside III-A2 exhibits inhibitory effects with IC50 values of 346-400 mol ratio/32 pmol TPA. and shows weak inhibitory effects on activation of (+/-)-(E)-methyl-2-[(E)-hydroxyimino]-5-nitro-6-methoxy-3-hexemide (NOR 1), a nitric oxide (NO) donor.